India's Central Drugs Standard Control Organization (CDSCO) has said it will start making surprise checks at Indian manufacturing sites.
The decision comes amid growing concern about the quality of medicines made in India and a series of FDA warnings. Several Indian plants have recently faced FDA actions following inspections including Lupin, Sun Pharma, Cadila Healthcare and Ipca Labs.
Inspections could begin as soon as next month, the agency official told Economic Times. Major deviations could result in cancelled licenses and legal action.
Read the ET article